炎症
免疫疗法
免疫系统
黑色素瘤
细胞因子
医学
白细胞介素
免疫学
癌症研究
生物
作者
Aslan Mansurov,Jun Ishihara,Peyman Hosseinchi,Lambert Potin,Tiffany M. Marchell,Ako Ishihara,John‐Michael Williford,Aaron T. Alpar,Michal M. Raczy,Laura T. Gray,Melody A. Swartz,Jeffrey A. Hubbell
标识
DOI:10.1038/s41551-020-0549-2
摘要
Checkpoint-inhibitor (CPI) immunotherapy has achieved remarkable clinical success, yet its efficacy in ‘immunologically cold’ tumours has been modest. Interleukin-12 (IL-12) is a powerful cytokine that activates the innate and adaptive arms of the immune system; however, the administration of IL-12 has been associated with immune-related adverse events. Here we show that, after intravenous administration of a collagen-binding domain fused to IL-12 (CBD–IL-12) in mice bearing aggressive mouse tumours, CBD–IL-12 accumulates in the tumour stroma due to exposed collagen in the disordered tumour vasculature. In comparison with the administration of unmodified IL-12, CBD–IL-12 induced sustained intratumoural levels of interferon-γ, substantially reduced its systemic levels as well as organ damage and provided superior anticancer efficacy, eliciting complete regression of CPI-unresponsive breast tumours. Furthermore, CBD–IL-12 potently synergized with CPI to eradicate large established melanomas, induced antigen-specific immunological memory and controlled tumour growth in a genetically engineered mouse model of melanoma. CBD–IL-12 may potentiate CPI immunotherapy for immunologically cold tumours. A collagen-binding interleukin-12 formulation intravenously injected into mice bearing established immunologically cold mouse tumours led to marked tumour remission, particularly when combined with checkpoint-inhibitor immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI